Key-points {#Sec1}
==========

Mitral insufficiency was common in TA patients with elevated ASO.There was a positive correlation between the titer of ASO and TA disease activity.Elevated ASO was risk factor to mitral involvement in untreated TA patients.

Background {#Sec2}
==========

Takayasu arteritis (TA) is a type of chronic, systemic vessel vasculitis that mainly involves the aorta and its major branches, and is more common in young women of Asian descent \[[@CR1]\]. Granulomatous inflammation in the media and adventitia is the pathological characteristic of TA, which results in fibrosis of large vessel walls, causing destruction of the elastic lamina and media \[[@CR2]\]. Although the etiology of TA is not clear, several studies may have indicated a link with an antigen-driven, immune-mediated process \[[@CR3], [@CR4]\]. Streptococcal antigen is considered to play a important role in the autoimmune reaction of streptococcal infection-related disorders \[[@CR5]\] and had been reported that TA sera reacted with streptococcal antigens \[[@CR6]\]. The most widely used clinical antibody assays involve antistreptolysin O (ASO), which is valuable in patients with possible group A β-hemolytic streptococcal infections. Both TA and rheumatic fever (RF) could present with cardiac manifestations \[[@CR7]\] and cause valvular disorders, resulting in systemic manifestations and making the diagnosis difficult \[[@CR8]\]. Some reported cases of TA were diagnosed a few years after an initial diagnosis of RF \[[@CR9], [@CR10]\]. Cardiac involvement is the key determinant of morbidity and mortality in both TA and RF. They share similar clinical and epidemiological characteristics \[[@CR11]\]. The incidence of cardiac valvular abnormalities in patients with TA is 7.0--36.7% \[[@CR12]\]. Previous researchers have found a poor prognosis of TA with cardiac valvular involvement, which should be taken into consideration \[[@CR13], [@CR14]\].

Therefore, this study aimed to investigate the clinical features of cardiac valvular involvement in TA patients with positive ASO titers and to analyze the correlation between ASO titers and untreated TA disease activity.

Methods {#Sec3}
=======

Patients {#Sec4}
--------

This is a retrospective study, approved by Capital Medical University affiliated Beijing Anzhen Hospital Ethics Committee (approval number: 2018054X). Seventy-four consecutive untreated TA patients were enrolled, according to the criteria for classifying TA developed by the American College of Rheumatology in 1990 \[[@CR15]\]. In total, 119 patients (74 were untreated) diagnosed with TA from January 2012 to December 2017 in Beijing Anzhen Hospital were recruited. We reviewed the records including demographic characteristics, clinical manifestations, laboratory tests, and imaging findings. Because acute RF affects cardiac valves, it was ruled out in the diagnosis of TA; therefore, there were no acute RF patients in our subjects. A modified version of Kerr's criteria (Kerr score) \[[@CR16]\] and the Indian Takayasu Clinical Activity Score (ITAS) \[[@CR17]\] were used to assess TA disease activity. The differences in the clinical characteristics and features of valvular involvement were compared in patients with or without elevated ASO.

Laboratory test {#Sec5}
---------------

Four milliliters of venous blood were collected and the serum was isolated. An automatic biochemical analyzer (7600--120, Hitachi, Tokyo, Japan) was used to analyze the serum parameters. After the patients were diagnosed with TA, their serum was collected and tested by the hospital laboratory department, and the results were reported. The ASO titer was determined by immune transmission turbidimetry (DiaSys Diagnostic Systems, Shanghai, China) with ASO ≤ 200 IU/mL as negative and ASO \> 200 IU/mL as positive. The erythrocyte sedimentation rate (ESR) was detected by the modified Westergren method.

Angiographic features and echocardiogram {#Sec6}
----------------------------------------

Magnetic resonance angiography, computed tomography angiography, and Doppler ultrasound were used to evaluate the thoracic and abdominal aorta and aortic branches. The lesions were classified according to the 1996 Numano classification \[[@CR18]\]. Echocardiograms were obtained with a 5-MHZ ultrasound probe (EPIQ 7C, Philips, the Netherlands) to evaluate the cardiac structure and function following published guidelines \[[@CR19]--[@CR21]\]. The severity of mitral and tricuspid regurgitation was graded by using quantitative values similar to those for aortic regurgitation according to the American Society of Echocardiography recommendations \[[@CR22]\].

Statistical analysis {#Sec7}
--------------------

According to the normality, numerical data were expressed as quartiles or means ± standard error. And unpaired *t-* test or Mann-Whitney U test were used to determine the differences between TA patients with positive and negative ASO. For qualitative parameters, χ^2^ test was used assessed the differences between two groups. Variables including ASO, ESR, IgA, IgG, Kerr Score, complement 3 (C3), and ITAS were computed to a multivariate backward stepwise logistic regression analysis (*p* = 0.05 entry and *p* = 0.10 removal criteria) to predict the independent risk factors for the valvular involvement in TA patients. All *p*-values were two-tailed and *p* \< 0.05 was interpreted as statistical significance. SPSS 16.0 statistical software (SPSS Inc., Chicago, IL, USA) was used for all the statistical analyses.

Results {#Sec8}
=======

General characteristic of untreated TA patients with positive ASO {#Sec9}
-----------------------------------------------------------------

There were 60 females (81.1%) and 14 males (18.9%). The median duraion of the disease was 48 (6.0, 144.0) months. Thirteen patients (17.6%) had a positive ASO titer (≥200 IU/ml), including 11 females (84.6%) and two males (15.4%). The average age of disease onset was 29.5 years (range 19.0--48.0) and the disease course ranged from 1 month to 3 years, with a median course of 6 months. The ASO titer ranged from 226 to 991 IU/ml. The most common angiographic type was Numano type V (30.8%, 4/13), followed by type I (23.1%, 3/13) and type IIb (23.1%, 3/13). In three patients (23.1%), the disease was complicated with pulmonary artery involvement and in one (7.7%), with coronary artery involvement (Table [1](#Tab1){ref-type="table"}). Table 1General characteristics of untreated TA patients with elevated ASO titerNoDisease duration (month)SymptomsNumano TypeFeatures of valvular involvementASO titer\
(IU/ml)11Left upper limb weaknessIIbMild mitral insufficiency2762120DizzinessV, P+Mild aortic insufficiency, mitral valve thickening, calcification and adhesion, moderate mitral stenosis and insufficiency9803144Dizziness, FatigueVMild aortic insufficiency, mitral valve calcification and prolapse, moderate mitral insufficiency, mild tricuspid insufficiency39845Chest tightnessVMitral annulus dilatation and valve edge thickening, severe mitral insufficiency, moderate tricuspid insufficiency, pulmonary hypertension (Systolic pulmonary artery pressure: 70 mmHg)580512Double upper limb weaknessIMild aortic insufficiency, mitral valve thickening, mild mitral insufficiency70966Headache, fever, FatigueIVNone56071Chest tightness, PalpitationsINone2698180Chest tightnessVSevere mitral insufficiency, mild tricuspid insufficiency, mild pulmonary insufficiency, pulmonary hypertension (Systolic pulmonary artery pressure: 50 mmHg)22691HeadacheIAortic valve edge thickening, mild mitral insufficiency, mild tricuspid insufficiency9911048Left upper limb weakness, PalpitationsIIa, P+Aortic valve edge thickening, severe aortic insufficiency, mild mitral insufficiency, severe tricuspid insufficiency,27411360FatigueIIINone279123Chest tightnessIIb, P + C+Aortic valve edge thickening, moderate aortic insufficiency, mild mitral insufficiency, mild tricuspid insufficiency, pulmonary hypertension (Systolic pulmonary artery pressure: 59 mmHg)2681360Double upper limb weaknessIIbMild aortic valve insufficiency544

Clinical features and angiographic manifestation in untreated TA patients with positive ASO {#Sec10}
-------------------------------------------------------------------------------------------

We compared the clinical manifestations of TA patients with positive or negative ASO. There were no significant differences in age, sex, duration of disease, and body mass index (BMI). There were also no significant differences in the clinical features and angiographic findings between the two groups. No significant difference in pulmonary artery and coronary artery involvement was observed, no atrial fibrillation was found in TA patients with valvular involvement (Table [2](#Tab2){ref-type="table"}). Table 2Clinical and lab features of untreated TA patients with positive or negative ASOASO positive\
*n* = 13ASO negative\
*n* = 61*P*-ValueFemale, n(%)11 (84.6)49 (78.7)0.720Age of onset (year)29.5 ± 10.033.5 ± 12.50.281Disease duration (month)6.0 (1.0, 102.0)48.0 (12.0, 168.0)0.081BMI (kg/m^2^)23.3 ± 3.522.8 ± 3.50.641Arteriosclerosis, n(%)3 (23.1)30 (49.2)0.086Hypertension, n(%)5 (38.5)13 (21.3)0.191T2DM, n(%)0 (0.0)4 (6.6)0.342Smoker, n(%)2 (15.4)11 (18.0)0.820Heart failure, n(%)4 (30.8)9 (14.8)0.168AF, n(%)0 (0.0)0 (0.0)--Aneurysms, n(%)3 (23.1)13 (21.3)0.966Dizziness, n(%)7 (53.9)27 (44.3)0.529Headache, n(%)2 (15.4)11 (18.0)0.820Asymmetry in BP, n(%)6 (46.2)23 (37.7)0.571Pulseless, n(%)4 (30.8)13 (21.3)0.462Chest tightness, n(%)5 (38.5)17 (27.9)0.448Chest pain, n(%)2 (15.4)15 (24.6)0.474Palpitations, n(%)3 (23.1)4 (6.6)0.065Carotidynia, n(%)1 (7.7)4 (6.6)0.882Erythema nodosum, n(%)1 (7.7)1 (1.6)0.222Blurred vision, n(%)0 (0.0)4 (6.6)0.342Fever, n(%)3 (23.1)9 (14.8)0.460Fatigue, n(%)4 (30.8)14 (23.0)0.551Weight loss, n(%)2 (15.4)3 (4.9)0.172Numano Type I3 (23.1)16 (26.2)0.086 IIa1 (7.7)3 (7.7)0.688 IIb3 (23.1)9 (14.8)0.460 III1 (7.7)4 (6.6)0.882 IV1 (7.7)1 (1.6)0.222 V4 (30.8)25 (41.0)0.493 P+3 (23.1)7 (11.5)0.267 C+1 (7.7)14 (23.0)0.214Note: *BMI* Body mass index; *T2DM* type 2 diabetes mellitus; *AF* atrial fibrillation; *P+* pulmonary artery involvement; *C+* coronary artery involvement

Comparison of laboratory values and disease activity between untreated TA patients with positive or negative ASO titers {#Sec11}
-----------------------------------------------------------------------------------------------------------------------

We compared the laboratory parameters and disease activity indexes of the two groups of patients. The results showed that the level of serum immunoglobulin (Ig) G in patients with positive ASO was significantly higher than that in patients with negative ASO (16.6 ± 4.1 vs 12.9 ± 3.7, *p* = 0.002). There was no significant difference in other parameters such as blood routine, liver function, kidney function, Ig A, IgM, complement 3 (C3), and complement 4 (C4). No significant difference in the disease activity index such as ESR, C-reactive protein (CRP), Kerr score and ITAS was found between the two groups (Table [3](#Tab3){ref-type="table"}). Table 3Laboratory parameters and disease activity of untreated TA patients with positive or negative ASOASO positive\
*n* = 13ASO negative\
*n* = 61*P*-ValueWBC(10^9^/L)7.0 ± 1.57.3 ± 2.20.643NE(10^9^/L)4.7 ± 1.44.7 + 1.70.979LY(10^9^/L)1.9 ± 0.62.1 ± 0.80.391RBC(10^12^/L)4.51 ± 0.414.5 ± 0.50.812Hb (g/L)122.8 ± 21.9124.2 ± 19.30.809PLT(10^9^/L)278.6 ± 107.2265.4 ± 90.10.645ALT (U/L)13.7 ± 10.518.2 ± 14.30.289Cr (μmol/l)63.1 ± 12.861.2 ± 31.10.833GLU (mmol/l)5.0 ± 0.65.2 ± 1.10.612HCY (μmol/l)11.5 ± 3.513.9 ± 9.50.388RF (IU/ml)6.5 (4.0,10.6)5.2 (3.1,11.7)0.222IL-6 (pg/ml)16.2 (3.3, 29.4)5.1 (2.3, 12.5)0.157TNF-α (pg/ml)9.6 (5.8, 22.6)20.3 (7.7, 48.7)0.210IgA (g/L)3.2 ± 1.42.5 ± 1.30.086IgG (g/L)16.6 ± 4.112.9 ± 3.70.002IgM (g/L)1.5 ± 0.61.4 ± 1.00.823IgE (g/L)35.6 (14.3, 176.7)17.0 (9.7, 87.3)0.151C3 (g/L)1.3 ± 0.31.2 ± 0.20.188C4 (g/L)0.2 ± 0.10.2 ± 0.10.657ESR (mm/1 h)23.0 (9.0, 72.0)18.0 (8.0, 39.0)0.352CRP (mg/L)4.5 (1.8, 23.6)2.2 (0.4, 21.5)0.334Kerr Score2.5 ± 0.72.4 ± 0.70.484ITAS8.9 ± 6.08.2 ± 4.80.682Note: *WBC* white blood cell; *LY* lymphocyte; *NE* neutrophil; *PLT* platelet; *RBC* red blood cell; *Hb* hemoglobin; *ALT* alanine aminotransferase; *Cr* creatinine; *GLU* Glucose; *HCY* homocysteine; *RF* rheumatoid factor; *IL* interleukin; *TNF* tumor necrosis factor; *Ig* immunoglobulin; *C3* complement 3; *C4* complement 4; *ESR* erythrocyte sedimentation rate; *CRP* C-reactive protein

We analyzed the correlation between ASO titer and the indexes of disease activity. The results showed that the titer of ASO was positively correlated with ESR (*r* = 0.291, *p* = 0.040), Kerr score (*r* = 0.286, *p* = 0.044), ITAS (*r* = 0.295, *p* = 0.037), IgG (*r* = 0.502, *p* = 0.000), and C3 (*r* = 0.285, *p* = 0.047). There was no correlation between ASO titer and CRP, IgA, IgM, and C4.

Cardiac valvular involvement in untreated TA patients with positive ASO {#Sec12}
-----------------------------------------------------------------------

Of the patients with positive ASO, 76.9% (10/13) had abnormal valvular findings. The proportion with abnormal valvular findings in patients with negative ASO was 65.6% (40/61), which was not significantly different. In each group, one case showed mitral stenosis and the others were valvular insufficiency. Mitral valve insufficiency was most common in patients with elevated ASO, accounting for 69.2% (9/13) (valve thickening in three patients, calcification in two, adhesion in one, and prolapse in one), which was not statistically significant compared with patients with normal ASO. Aortic valve insufficiency (46.2%, 5/13) and tricuspid valve insufficiency (46.2%, 5/13) were not significantly different between the two groups. One patient in each group had pulmonary valve insufficiency, one positive ASO patient showed stenosis complicated with insufficiency of the mitral valve, which was not significantly different between groups. The incidence of multiple valve involvement in the positive ASO group was 61.5% (8/13), which was higher than that in the negative ASO group (34.4%, 21/61), although there was no significant difference (*p* = 0.069). Single valve involvement was found in two cases (15.4%) in the ASO positive group and 19 cases (31.2%) in the ASO negative group, with no significant difference.

The proportion of moderate to severe mitral insufficiency in the ASO positive group was significantly higher than that in the ASO negative group (30.8% vs 1.6%, *p* = 0.000). There was no significant difference between the two groups in mild mitral valve insufficiency (38.5% vs 45.9%, *p* = 0.624). Two patients in the positive ASO group and one in the negative ASO group had moderate to severe tricuspid insufficiency; the difference was statistically significant (15.4% vs 1.6%, *p* = 0.023), there was no significant difference between the two groups in mild tricuspid insufficiency (30.8% vs 27.9%, *p* = 0.833). There was no significant difference in aortic insufficiency between the two groups (Table [4](#Tab4){ref-type="table"}). Table 4Features of cardiac valvular involvement of untreated TA patients with positive or negative ASOValvular involvementASO positive\
*n* = 13ASO negative\
*n* = 61*P*-ValueTotal, n(%)10 (76.9)40 (65.6)0.427Aortic Valve insufficiency, n(%)6 (46.2)24 (39.3)0.650 Mild4 (30.8)18 (29.5)0.828 Medium to severe2 (15.4)6 (9.8)0.559Mitral valve insufficiency, n(%)9 (69.2)29 (47.5)0.155 Mild5 (38.5)28 (45.9)0.624 Medium to severe4 (30.8)1 (1.6)0.000Mitral valve stenosis, n(%)1 (7.7)1 (1.6)0.222Tricuspid valve insufficiency, n(%)6 (46.2)16 (26.2)0.154 Mild4 (30.8)17 (27.9)0.833 Medium to severe2 (15.4)1 (1.6)0.023Pulmonary insufficiency (mild), n(%)1 (7.7)1 (1.6)0.222Multiple valve involvement, n(%)8 (61.5)21 (34.4)0.069Single valve involvement, n(%)2 (15.4)19 (31.2)0.252

We further analyzed the features of transesophageal echocardiography between the two groups in TA patients with valvular lesions. We found that 50% of the patients with elevated ASO had valve thickening (5/10), including 3 patients with aortic valve and 2 patients with mitral valve, which were significantly higher than those in ASO negative group (10.0%, 4/40) (3 patients with aortic valve and 1 patient with mitral valve) (*p* = 0.003). The ejection fraction was significantly lower in ASO positive group than that of normal ASO group (54.7 ± 13.8% vs 62.4 ± 9.2%, *p* = 0.042) (Table [5](#Tab5){ref-type="table"}). Table 5Features of transesophageal echocardiography between the two groups in TA patients with valve involvementParametersASO positive\
*n* = 10ASO negative\
*n* = 40*P*-ValueValvular prolapse, n(%)1 (10.0)3 (7.5)0.794Valvular thickening, n(%)5 (50.0)4 (10.0)0.003Valvular contracture, n(%)0 (0.0)1 (2.5)--Left ventricular end-diastolic dimension, (mm)52.7 ± 12.547.7 ± 5.90.059Ejection fraction, (%)54.7 ± 13.862.4 ± 9.20.042Left atrium enlargement, n(%)3 (30.0)14 (35.0)0.765Left ventricular diastolic dysfunction, n(%)2 (20.0)19 (47.5)0.115Pulmonary hypertension, n(%)3 (30.0)3 (7.5)0.050

Analysis of the risk factors of mitral and tricuspid valvular insufficiency in untreated TA patients {#Sec13}
----------------------------------------------------------------------------------------------------

We used logistic stepwise regression analysis to analyze the effects of ASO, ESR, IgA, IgG, Kerr score, ITAS, and C3 on mitral and tricuspid regurgitation. The results showed that the risk of mitral regurgitation in patients with elevated ASO titer was 3.9 times higher than that in patients with normal ASO (*p* = 0.053, OR = 3.929, 95% CI: 0.983--15.694). The risk of moderate to severe mitral regurgitation in patients with positive ASO was 41.6 times higher than that in patients with normal ASO (*p* = 0.002, OR = 41.600, 95% CI: 3.867--447.559).

Discussion {#Sec14}
==========

This study compared the clinical manifestations, laboratory findings, and heart valve disease characteristics of untreated TA patients with or without elevated ASO. We report, for the first time, that the proportion of mitral insufficiency is closely related with elevated ASO in untreated TA patients. Serum IgG was significantly higher in the ASO positive group than in the ASO negative group. In patients with positive ASO, the titer of ASO was positively correlated with ESR, IgG, and C3, and was paralleled to the TA disease activity index Kerr Score and ITAS.

Although the etiology of TA is unknown, it has long been suggested that TA pathogenesis is related to infections. Pathogen-triggered autoimmune response has also been proposed; however, convincing proof to support an association between streptococcus infection and TA is still lacking \[[@CR23]\]. Both TA and RF could cause valvular abnormalities and present systemic clinical manifestations. Similar to our study, the association between an elevated ASO titer and TA has been described previously, with 19% of patients exhibiting an ASO titer twice the upper limit of normal \[[@CR24]\]. Gan-gahanumaiah et al. reported a case of a female TA patient aged 29 years with heart failure, with a past history of RF, whose echocardiography suggested mitral and aortic regurgitation, and pulmonary hypertension \[[@CR25]\]. Another case reported an 11-year-old boy with a markedly elevated ASO titer, who was initially diagnosed with acute RF; however, after admission, aortic wall thickening and enhancement were found on magnetic resonance angiography images, leading to a diagnosis of TA \[[@CR7]\].

A previous study retrospectively assessed cardiac valvular structural abnormalities and dysfunctions and found that valvular involvement is common in TA patients, with the female to male ratio being nearly 5:1, similar to our result of 4.3:1 \[[@CR26]\]. Aortic insufficiency was the most common finding in TA patients, followed by mitral insufficiency \[[@CR12], [@CR27], [@CR28]\]. In this study, mitral insufficiency and aortic insufficiency were observed in 69.23 and 46.15% of TA patients with elevated ASO, respectively; therefore, mitral valve involvement was more likely in TA patients with elevated ASO. As shown in Fig. [1](#Fig1){ref-type="fig"}, a 32-year-old TA patient with elevated ASO, two - dimensional echocardiography suggested mitral valve calcification and prolapse, and Color Doppler ultrasound detected a large number of regurgitation signals in the left atrium. Moderate and severe mitral valve involvement was significantly more common in patients with ASO positive titers than in patients with normal ASO titers. Moderate and severe tricuspid insufficiency in TA patients with elevated ASO titers was also more frequent than that in those with normal ASO titers. Jing Li \[[@CR12]\] reported that valvular abnormalities were found in 81.7% of TA patients, including single valve involvement in 67.2% and multiple valve involvement in 32.8%. In contrast, our study found that patients with elevated ASO, 61.5% of the TA patients exhibited multiple valvular lesions compared to 15.4% of patients with single valve involvement. These results suggest that streptococcus may aggravate valve damage in patients with TA. The remodeling of cardiac chambers may implicate the adjacent atrioventricular valves destroying the structure and function, resulting in dilatation of the valvular annulus and contortion of the subvalvular apparatus. This process may deteriorate heart failure, leading to severer manifestations and poorer prognosis \[[@CR29]\], which is the main reason for mortality in TA patients \[[@CR30]\]. According to our data, patients with valve problems may have lower EF, and that this would be a vicious circle between more severe valve problems and heart failure. Fig. 1Echocardiography shows moderate mitral insufficiency in a 32-year-old TA patient with elevated ASO. Two - dimensional echocardiography suggested mitral valve calcification and prolapse (**a**), and Color Doppler ultrasound detected a large number of regurgitation signals in left atrium (**b**)

*Streptococcus pyogenes* activates both the innate and adaptive immune reactions. Multiple immune cells are involved including neutrophils, lymphocytes, monocytes, and macrophages. Several immune-mediated injury mechanisms are involved in valvular damage. Similar to the pathogenesis of rheumatic heart disease, peptides derived from cardiac endothelial cells in susceptible individuals resembled the epitopes of Streptococcus, and became self-antigens by this "molecular mimicry" phenomenon. The initial event was the recognition of self-antigens on antigen presenter cells, producing autoantibodies and autoreactive T cells that react against the patient's self-antigens.

Autoantibodies activated endothelial cells, and promoted vascular cell adhesion molecule 1 expression. The following process was T-lymphocyte infiltration in the avascular valve matrix, resulting Th1-cytokine-mediated immune injuries. Furthermore, by epitope spreading, other valvular self-antigens including vimentin and collagen can be recognized and the immune response, amplified. Additionally, patients with group A streptococcal infections have elevated numbers of Th17 cells and higher serum IL-17 concentrations, indicating that Th17 responses occur in RF. These autoimmune responses were considered in association with TA \[[@CR31], [@CR32]\].

Recent studies have found that recombinant human α-enolase specific positive signals were detected in 57.1% of TA patients and specific streptococcal α-enolase positive signals were detected in 14.3%TA patients \[[@CR6]\]. Streptococcal M protein binding to type IV collagen in the basement membrane can induce inflammation and fibrosis of valvular cusps \[[@CR33]\]. Carbohydrate antigen (N-acetylβ-D-glucosamine) and Group A streptococcus M protein are believed to share the same epitope with human myosin and cardiac valve laminin; this structural similarity may result in antibody-mediated valve structure damage \[[@CR34]\]. It was found that there was a large number of peripheral B-cells of active TA patients, and there were CD20+ B cells surrounding the granulomatous lesions \[[@CR35]\]. Accordingly, it has been reported that the serum levels of antibodies that react with self-endothelial cells are elevated in TA patients. In vitro experiments verified that the autoantibodies induced endothelial cell proliferation through the mammalian target of rapamycin (mTOR) pathway \[[@CR36]\]. We found that the serum IgG levels were markedly higher in TA patients with elevated ASO titers than in those with negative ASO titers and had a positive correlation with the ASO titers, suggesting that autoantibodies activated by the immune response after a streptococcal infection might play an key role in valve damage.

The main limitations were the retrospective nature of this study, because TA is a rare disease. In addition, our subjects were untreated patients, so the sample size was relatively small, and most of the patients are female. This study included all patients with valvular involvement because the cause of valvular insufficiency could not be fully determined; however, we did further divide the patients into mild and moderate to severe groups.

Conclusions {#Sec15}
===========

In conclusion, we found that the proportion of mitral valve and tricuspid insufficiency in TA patients with elevated ASO titer was obviously higher than that in TA patients with normal ASO. ASO titer was positively correlated with IgG, ESR and C3 in TA patients with elevated ASO titer, which was parallel with the TA disease activity index. These results indicate that an elevated ASO is associated to valvular involvement in TA, which is closely related to mitral insufficiency. In TA patients with elevated ASO titer, cardiac valvular involvement should be monitored carefully.
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